Genscript bio (01548) issued 4.18 million shares due to options exercised.

Genscript bio (01548) announced that the company will... on November 18, 2024, according to the 2015...

Zhitong FinanceNov 18 07:47 ET

Genscript Biotech Enters Sub-License Contract for Anti-PD-1 Single Domain Antibodies

MT NewswiresNov 15 03:33 ET

Genscript bio (01548.HK): Nanjing Pengbo has reached a licensing agreement with Lixin Medical Technology Co., Ltd.

Gelonghui November 15th | Genscript Bio (01548.HK) announced that on November 12, 2024, its non-wholly owned subsidiary Nanjing Pongbo Technology Co., Ltd. ("Nanjing Pongbo") entered into a restated and amended license agreement with Lixin Pharmaceutical Technology Co., Ltd. ("Lixin"). Pursuant to the agreement, Nanjing Pongbo agrees to grant Lixin an exclusive global transferable license, with the right to further sublicense, allowing it to develop, produce, commercialize, and

Gelonghui FinanceNov 14 19:32 ET

Genscript Bio (01548.HK): John Anthony Quelch has been appointed as an independent non-executive director.

Genscript Bio (01548.HK) announced on November 15th that John Anthony Quelch has been appointed as an independent non-executive director and a member of the global strategy committee, effective from November 14, 2024.

Gelonghui FinanceNov 14 18:24 ET

Press Release: Seasoned Marketing Executive Joins GenScript as Chief Marketing Officer

Dow JonesNov 13 10:00 ET

Genscript Bio Associate Legend Biotech's Loss Doubles in Q3

MT NewswiresNov 13 00:15 ET